Tiziana Life Sciences Ltd

NasdaqCM:TLSA

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United Kingdom

Market Cap

USD 204.48 M

Share Price

USD 1.75

Avg Daily Volume

465,777

Change (1 day)

10.76%

Change (1 year)

80.41%

Change (YTD)

151.36%

Tiziana Life Sciences Ltd Share Price on June 25, 2025: USD 1.75

Tiziana Life Sciences Ltd Share Price is USD 1.75 on June 25, 2025, a 80.41% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Tiziana Life Sciences Ltd 52-week low Share Price is USD 1.75 on June 25, 2025, which is 0.00% below the current Share Price.
Tiziana Life Sciences Ltd 52-week low Share Price is USD 0.64 on June 25, 2025, which is -63.26% below the current Share Price.
Tiziana Life Sciences Ltd average Share Price for the last 52 weeks is USD 1.05.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NasdaqCM: TLSA

Tiziana Life Sciences Ltd

CEO	Dr. Ivor R. Elrifi Ph.D.
IPO Date	Nov. 20, 2018
Location	United Kingdom
Headquarters	55 Park Lane
Employees	9
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.